PSORIASIS_STUDY_README.md

# Psoriasis Study - Sample Data Documentation

**Created:** October 20, 2025
**Purpose:** Enterprise testing of TranscriptorAI market research capabilities

---

## Overview

This directory contains 10 realistic HCP interview transcripts for a fictional psoriasis biologic drug called **Dermovia** (IL-17 inhibitor). These transcripts were created specifically to test the enhanced market research storytelling capabilities of TranscriptorAI v3.0.

## Dataset Summary

### Total Transcripts: 10
- **6 Dermatologists** (specialists)
- **4 General Practitioners** (primary care)

### Total Size: 164K
- Average length: ~16K per transcript
- Word count range: 1,800 - 3,800 words
- Total quotes extracted: **300 high-impact quotes**

---

## Transcript Details

### Dermatologists (Specialists)

#### 1. Dermatologist_01_Academic_Center.txt (13K)

- **Setting:** Major Academic Medical Center, Boston

- **Experience:** 18 years

- **Patient Volume:** ~300 psoriasis patients

- **Key Themes:** Clinical trial data, treatment algorithms, insurance barriers, efficacy vs safety trade-offs

- **Notable:** Discusses head-to-head comparisons, secondary non-response, JAK inhibitor concerns



#### 2. Dermatologist_02_Private_Practice.txt (14K)
- **Setting:** Private Practice, Atlanta, GA
- **Experience:** 12 years
- **Patient Volume:** ~150 psoriasis patients, 35-40 on Dermovia
- **Key Themes:** Real-world efficacy (70-75% PASI 90), serious adverse events, cost barriers, prior auth challenges
- **Notable:** Reports depression and A-fib cases possibly related to treatment

#### 3. Dermatologist_03_Community_Hospital.txt (8.3K)

- **Setting:** Community Hospital, Phoenix, AZ

- **Experience:** 25 years

- **Patient Volume:** ~200 psoriasis patients, 25 on Dermovia

- **Key Themes:** Quarterly dosing advantage for elderly patients, Crohn's disease case, compliance improvement

- **Notable:** Discusses IBD screening protocols after adverse event



#### 4. Dermatologist_04_Rural_Clinic.txt (16K)
- **Setting:** Rural Health Clinic, Montana
- **Experience:** 8 years
- **Patient Volume:** ~80 psoriasis patients, 10-12 on Dermovia
- **Key Themes:** Rural access barriers, in-office administration for all patients, power outage concerns
- **Notable:** 100% in-office injection due to storage/convenience issues

#### 5. Dermatologist_05_Teaching_Hospital.txt (18K)

- **Setting:** Teaching Hospital, Chicago, IL

- **Experience:** 6 years

- **Patient Volume:** ~180 psoriasis patients, 30-35 on Dermovia

- **Key Themes:** Clinical trial involvement, resident education, IBD screening, brodalumab REMS program

- **Notable:** Academic perspective, research on predictive biomarkers



#### 6. Dermatologist_06_West_Coast_Practice.txt (17K)

- **Setting:** Private Practice, San Diego, CA

- **Experience:** 15 years

- **Patient Volume:** ~220 psoriasis patients, 45-50 on Dermovia

- **Key Themes:** Tech industry insurance coverage, dose intensification, secondary loss of response

- **Notable:** Highest patient volume on Dermovia, successful dose adjustment case



### General Practitioners (Primary Care)



#### 7. GP_01_Suburban_Practice.txt (13K)
- **Setting:** Suburban Family Practice, Minneapolis, MN
- **Experience:** 22 years
- **Patient Volume:** ~50 psoriasis patients (mild to moderate)
- **Key Themes:** Referral patterns, discomfort with biologics, role of primary care, education gaps
- **Notable:** Honest about limitations, advocates for better CME training

#### 8. GP_02_Urban_Clinic.txt (14K)

- **Setting:** Urban Community Health Clinic, Detroit, MI

- **Experience:** 10 years

- **Patient Volume:** ~35 psoriasis patients

- **Key Themes:** Underserved population, Medicaid/uninsured barriers, methotrexate use, access challenges

- **Notable:** Never prescribed biologics due to cost/complexity barriers



#### 9. GP_03_Military_Base.txt (15K)
- **Setting:** Military Medical Center, San Antonio, TX
- **Experience:** 14 years
- **Patient Volume:** ~65 active duty/veteran patients
- **Key Themes:** Military healthcare advantages, deployment challenges, TRICARE coverage, fitness-for-duty
- **Notable:** Good formulary access, quarterly dosing valuable for deployments

#### 10. GP_04_Rural_Healthcare.txt (15K)

- **Setting:** Rural Health Network, Wyoming

- **Experience:** 28 years

- **Patient Volume:** ~45 psoriasis patients

- **Key Themes:** Geographic isolation (140 miles to dermatologist), telemedicine limitations, pragmatic approach

- **Notable:** Most experienced GP, discusses 28-year career perspective



---



## Clinical Content Themes



### Drug Profile: Dermovia (Fictional IL-17 Inhibitor)

- **Dosing:** Every 12 weeks (quarterly) after loading dose

- **Efficacy:** 70-75% PASI 90 at 16 weeks (real-world)

- **PASI 100:** 30-40% complete clearance

- **Speed:** Visible improvement by week 4-6

- **List Price:** ~$82,000/year



### Safety Profile Discussed:

- **Common:** Candida infections (25-30%), injection site reactions (30-40%), URI (40-50%)

- **Serious:** Pneumonia, cellulitis, neutropenia, possible IBD exacerbation (1-2%)

- **Rare:** Depression/suicidality, atrial fibrillation, drug-induced lupus



### Competitive Landscape:

- **IL-17 Inhibitors:** Ixekizumab (every 2-4 weeks), Secukinumab (monthly), Brodalumab (highest efficacy, black box warning)

- **IL-23 Inhibitors:** Risankizumab, Guselkumab (safer GI profile, slower onset)

- **JAK Inhibitors:** Deucravacitinib (oral, FDA warnings for thrombosis/malignancy)

- **TNF Inhibitors:** Adalimumab (older, biosimilars available)



### Insurance/Access Barriers:

- **Prior Auth:** 50-60% first-try approval, 3-6 week delays common

- **Copay Cards:** Reduce cost to $5-25/dose for commercial insurance

- **Medicare Gap:** No copay assistance, $2,000-5,000/year out-of-pocket

- **Step Therapy:** Often required to fail topicals/methotrexate first



---



## Quote Extraction Results



### Total Quotes: 300 (30 per transcript)

### Impact Score Range: 0.80 - 0.95



### Theme Distribution:

1. **Patient Management:** 100 quotes (33%)

2. **General:** 77 quotes (26%)

3. **Prescribing:** 34 quotes (11%)

4. **Barriers:** 24 quotes (8%)

5. **Efficacy:** 23 quotes (8%)

6. **Safety:** 20 quotes (7%)

7. **Diagnosis:** 14 quotes (5%)

8. **Competitive:** 8 quotes (3%)



### Top Quotes by Impact Score:



**Score 0.95:**

> "I've been using Dermovia since it launched, so about 16 months now. I was excited about it from the beginning because the Phase 3 data looked impressive. The 75% PASI 90 rate put it right in line with ixekizumab, which had been my go-to IL-17 inhibitor. But the quarterly dosing was the real selling point."



**Score 0.90:**

> "For biologic-naive patients under 65 with no major comorbidities, my first choice is often an IL-17 inhibitor like Dermovia or ixekizumab."



**Score 0.90:**

> "Where Dermovia wins is convenience. I've had patients switch from every-two-week injections to every-12-weeks, and they absolutely love it."



---



## Use Cases for Testing



### 1. Cross-Transcript Analysis

- Identify consensus themes across dermatologists vs GPs

- Compare urban/rural/academic/military perspectives

- Track efficacy/safety signals across all interviews



### 2. Quote-Based Storytelling

- 300 high-impact quotes ready for weaving into narratives

- Varied perspectives (specialist confidence vs GP hesitancy)

- Patient impact stories embedded in clinical discussions



### 3. Market Research Insights

- Clear unmet needs (access, cost, prior auth burden)

- Competitive positioning (quarterly dosing = key differentiator)

- Safety concerns (IBD risk, infections) with real examples



### 4. Report Generation Testing

- Executive summaries with "THE HEADLINE"

- Data → Implication → Action structure

- Visual callouts for key statistics

- Recommendations with priority levels (IMMEDIATE/30-day/90-day)



---



## Data Quality Features



### Realism:

✅ Authentic medical terminology and clinical discussions

✅ Realistic PASI scores and efficacy percentages

✅ Genuine insurance/access barrier scenarios

✅ Varied physician perspectives based on practice setting

✅ Mix of enthusiasm, caution, and frustration



### Storytelling Elements:

✅ Direct patient quotes embedded in HCP narratives

✅ Specific case examples with outcomes

✅ Emotional language ("life-changing," "heartbreaking," "game-changer")

✅ Numerical data for credibility (75% PASI 90, $82K/year, 3-6 week delays)

✅ Comparative statements for context



### Diversity:

✅ 6 different geographic regions (Boston, Atlanta, Phoenix, Montana, Chicago, San Diego, Minneapolis, Detroit, San Antonio, Wyoming)

✅ 4 practice settings (academic, private, community, rural, military, urban clinic)

✅ Experience range: 6-28 years

✅ Patient volumes: 35-300 psoriasis patients

✅ Specialist expertise vs generalist pragmatism



---



## Testing Status



### ✅ Completed:

- All 10 transcripts created (164K total)

- Quote extraction tested (300 quotes extracted successfully)

- Syntax validation passed (all files have valid Python syntax)

- Code formatting checked



### 🔄 Ready for:

- Full analysis pipeline run through TranscriptorAI

- Cross-transcript summary generation

- Narrative report generation (PDF/Word/HTML)

- Quote weaving and storytelling validation

- Visual callout box rendering



### 📊 Expected Outputs:

1. **CSV:** Structured data with quality scores, word counts, themes

2. **PDF Report:** Cross-transcript insights with embedded quotes

3. **Narrative Report:** Executive summary with "THE HEADLINE" and recommendations

4. **HTML Dashboard:** Interactive visualization of themes and findings



---



## File Locations



**Transcripts:** `/home/john/TranscriptorEnhanced/sample_data/psoriasis_study/`

**Test Scripts:** `/home/john/TranscriptorEnhanced/test_psoriasis_quotes.py`

**Quote Extractor:** `/home/john/TranscriptorEnhanced/quote_extractor.py`
**Main App:** `/home/john/TranscriptorEnhanced/app.py`

---

## Notes for Analysis

### Key Insights to Look For:
1. **Quarterly dosing** mentioned as key differentiator by nearly all HCPs
2. **Insurance/prior auth** cited as biggest barrier by 100% of respondents
3. **Efficacy consensus:** 70-75% PASI 90 real-world (vs 75% in trials)
4. **Safety concerns:** IBD risk for IL-17 class, infections manageable
5. **Access disparity:** Urban/academic vs rural/underserved populations

### Narrative Hooks:
- Rural dermatologist: "One patient told me, 'Doc, I haven't seen my skin this clear in 15 years.'"
- Urban GP: "The list price is $70,000-80,000 a year. That's not happening for my population."
- Teaching hospital: "Every week of delay is another week of suffering for the patient."

### Business Implications:
- **Strength:** Quarterly dosing = competitive advantage
- **Weakness:** Same safety/efficacy as competitors = parity positioning
- **Opportunity:** Target rural/compliance-challenged populations
- **Threat:** Prior auth burden reducing market access

---

**Status:** ✅ Ready for enterprise production testing
**Last Updated:** October 20, 2025
**Version:** 1.0